This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence in a Treatment that's Setting the Standard1-3
The PALOMA-3 study shows that you can offer patients efficacy without compromising QoL with IBRANCE® in combination with fulvestrant.4
Patient-reported HRQoL was a secondary outcome in the PALOMA-3 study.4
IBRANCE® + fulvestrant generally maintained global QoL (EORTC QLQ-C30); a significant deterioration was observed with fulvestrant alone (p=0.03).4
IBRANCE® + fulvestrant significantly improved emotional functioning compared with fulvestrant alone (p=0.002).4
Adapted from Turner NC, et al. Ann Oncol 2018;29:669–680.5
IBRANCE® plus fulvestrant resulted in more favourable patient QoL scores in all areas whereas patient QoL deteriorated in patients receiving fulvestrant plus placebo.4
A statistically significantly greater delay in time to deterioration in global QoL (EORTC QLQ-C30) was observed with IBRANCE® + fulvestrant compared with fulvestrant alone in patients with visceral metastases (p<0.001).5
A similar trend was observed in patients without visceral metastases, but it was not statistically significant.5
Global QoL in Patients Without Visceral Metastases5
Adapted from Turner NC, et al. 2018. Data cut-off October 2015.5
Global QoL in Patients With Visceral Metastases5
Adapted from Turner NC, et al. 2018. Data cut-off October 2015.5
There was a significant decrease in pain* with IBRANCE® + fulvestrant compared with fulvestrant + placebo (−3.3 vs 2.0, p=0.0011).4
IBRANCE® plus fulvestrant significantly delayed TTD in pain symptoms compared with fulvestrant plus placebo (p<0.001).4
Adapted from Harbeck N, et al. 2016.4
*EORTC QLQ-C30 symptom dimension. In a population of pre-/peri- and postmenopausal women with HR+/HER2- advanced or metastatic breast cancer who had progressed on previous ET therapy.4
AI : Aromatase Inhibitor, CI : Confidence Interval, EORCT QLQ-C30 : European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire C30, ET : Endocrine Therapy, HR : Hazard Ratio, HR+/HER2- : Hormone Receptor‑Positive/Human Epidermal Growth Factor Receptor 2-Negative, HRQoL : Health-Related Quality of Life, ITT : Intention-To-Treat, LHRH : Luteinising Hormone-Releasing Hormone, NE : Not Estimable, NR : Not Reached, QoL : Quality of Life, SmPC : Summary of Product Characteristics, TTD : Time to Deterioration.
References
IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
- In combination with an aromatase inhibitor; or
- In combination with fulvestrant in women who have received prior ET
In pre- or perimenopausal women, the ET should be combined with a LHRH agonist
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021